Browsing by Author "Younis, Nour K."

Now showing items 1-5 of 5

    • 2-Nucleobase-substituted 4,6-Diaminotriazine Analogs: Synthesis and Anti-cancer Activity in 5-Fluorouracil-Sensitive and Resistant Colorectal Cancer Cells. 

      Hamze, Khalil; Abdallah, Rola H; Younis, Nour K; Fardoun, Manal; Darwiche, Nadine; ... more authors ( Bentham Science Publishers , 2022 , Article)
      Cancer continues to be the second leading cause of death worldwide with colorectal cancer (CRC) being the third most common type. Despite significant advances in cancer therapies, current treatment of CRC remains suboptimal. ...

    • Covid-19 in pediatric patients: A focus on CHD patients 

      Zareef, Rana O.; Younis, Nour K.; Bitar, Fadi; Eid, Ali H.; Arabi, Mariam ( Frontiers Media S.A. , 2020 , Article)
      Coronavirus disease 2019 (COVID-19) is a global pandemic caused by SARS-CoV-2 virus. As of the 30th of September 2020, around 34,000,000 cases have been reported globally. Pediatrics with underlying congenital heart disease ...

    • COVID-19: potential therapeutics for pediatric patients 

      Younis, Nour K.; Zareef, Rana O.; Fakhri, Ghina; Bitar, Fadi; Eid, Ali H.; ... more authors ( Springer , 2021 , Article Review)
      The global spread of COVID-19 has imparted significant economic, medical, and social burdens. Like adults, children are affected by this pandemic. However, milder clinical symptoms are often experienced by them. Only a ...

    • Hydroxychloroquine in COVID-19 Patients: Pros and Cons 

      Younis, Nour K.; Zareef, Rana O.; Al Hassan, Sally N.; Bitar, Fadi; Eid, Ali H.; ... more authors ( Frontiers Media S.A. , 2020 , Article)
      The pandemic of COVID-19, caused by SARS-CoV-2, has recently overwhelmed medical centers and paralyzed economies. The unparalleled public distress caused by this pandemic mandated an urgent quest for an effective approach ...

    • Nanomedicine for Cancer. 

      Younis, Nour K; Yassine, Hadi M; Eid, Ali H ( Bentham Science Publishers , 2022 , Other)
      Over the past decades, oncology has occupied the lion’s share of all nanomedical applications [1-3]. In 2020, up to 65% of the clinical trials involving nanomaterials were attending to cancer therapeutics and diagnostics ...